GlassScriptPhysician profile
William B Womack
NPI 1679678205
$2,440.39
in general payments reported to CMS, 2019-2025
23 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $323 · 2021: $401 · 2022: $369 · 2023: $279 · 2024: $341 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $870.86 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $244.46 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $204.03 | 2019-2021 | |
| Lilly USA, LLC | $200.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $178.84 | 2019-2024 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $88.97 | 2019-2025 | Airsupra, Farxiga |
| Nevro Corp. | $86.19 | 2021 | |
| Glaxosmithkline, LLC. | $80.81 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $75.88 | 2022-2024 | |
| Dexcom, INC. | $51.02 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $43.46 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $37.32 | 2019 | |
| Exact Sciences Corporation | $37.04 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.54 | 2020-2021 | |
| Viatris Specialty LLC | $33.30 | 2025 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $31.82 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.65 | 2019-2020 | |
| Astellas Pharma US INC | $29.92 | 2020-2023 | Veozah |
| Xeris Pharmaceuticals, INC. | $25.00 | 2024 | Keveyis |
| Verona Pharma, INC. | $15.61 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $13.33 | 2023 | Verquvo |
| Abbvie INC. | $12.94 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Womack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.